Autopsy report · NCT02736318

OD-PHOENIX in Talus Osteochondral Lesion

“Low accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 4 years 7 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

TBF Genie Tissulaire

Sponsor type

Industry

Conditions

Talus Osteochondral Defect

Interventions

OD-PHOENIX

Participants

12

Sites

2

Countries

Belgium, Israel

Trials that died the same way

• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (92% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (88% match in meaning)
• High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
  “Insufficient rate of accrual” (87% match in meaning)
• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
  “insufficient accrual rate” (85% match in meaning)
• Education for Prevention of Melanoma in Hispanic Populations
  “Low/slow accrual” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.